SIMILAC ADVANCE EARLYSHIELD OTC
Generic Name and Formulations:
Protein (nonfat milk, whey protein concentrate), carbohydrate (lactose), fat (high-oleic safflower, coconut, soy, c. cohnii, m. alpina oils), galacto-oligosaccharides, beta-carotene, lutein, lycopene, monoglycerides, soy lecithin, iron 1.8mg/100Cal, vitamins, minerals, taurine, L-carnitine, nucleotides; contains DHA 0.15% and ARA 0.40%.
Indications for SIMILAC ADVANCE EARLYSHIELD:
Feeding of normal infants as supplement or alternative to breast milk.
Prepared as directed provides 20Cal/oz.
Infant formula with iron.
Ready-to-feed—2oz, 8oz, 32oz; Nipple-ready bottle—2oz, 8oz; Liq conc—13oz; Pwd—12.9oz; Singles (pwd pkts)—16; SimplePac (pwd)—23.2oz, 34oz
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments